Media coverage about Cerecor (NASDAQ:CERC) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cerecor earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.7313332439389 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
Shares of NASDAQ CERC traded down $0.01 during mid-day trading on Thursday, hitting $3.83. The company had a trading volume of 2,222 shares, compared to its average volume of 129,979. The stock has a market cap of $121.14 million, a PE ratio of 9.17 and a beta of 1.30. Cerecor has a 1 year low of $0.42 and a 1 year high of $5.74. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.67 and a current ratio of 0.91.
Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Friday, May 11th. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $4.48 million during the quarter. Cerecor had a net margin of 31.17% and a return on equity of 59.50%. sell-side analysts predict that Cerecor will post -0.39 EPS for the current year.
In other Cerecor news, Director Armistice Capital, Llc bought 41,096 shares of Cerecor stock in a transaction that occurred on Monday, April 16th. The stock was acquired at an average cost of $3.36 per share, for a total transaction of $138,082.56. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Peter Greenleaf bought 12,500 shares of Cerecor stock in a transaction that occurred on Friday, May 18th. The shares were acquired at an average price of $3.98 per share, with a total value of $49,750.00. Following the completion of the transaction, the chief executive officer now owns 412,500 shares of the company’s stock, valued at $1,641,750. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 627,088 shares of company stock valued at $2,224,531. 80.20% of the stock is owned by company insiders.
Cerecor Company Profile
Cerecor Inc, a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.